Clinical trials: Anti-Xa Activity
Venous Thromboembolism
Thromboprophylaxis in Critically Ill Patients
Intensive care patients are at high risk to develop deep venous thrombosis and pulmonary embolism. Despite anticoagulation with heparin 7% of ICU patients suffer from this serious complication.
- Trial name
- NCT00437697
- Testing
- dalteparin
- Where
- Austria
- Volunteers
- 90 people
- Sponsor
- Medical University of Vienna
Thrombosis, Pulmonary Embolism
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients
The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically…
- Conditions
- Thrombosis, Pulmonary Embolism, Enoxaparin
- Trial name
- AntiXa-ICU (NCT06357403)
- Testing
- Anti-factor Xa activity calibrated for enoxaparin
- Where
- 3 sites in Austria
- Volunteers
- 1,300 people
- Sponsor
- Medical University of Vienna
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Critical Illness, Thrombosis
Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients
Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors.
- Trial name
- NCT06055907
- Testing
- Serum anti-Xa activity
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Medical University of Gdansk
Gene Polymorphism, Edoxaban
Prospective Observational Association Between SLCO1B1 Gene Polymorphism and the Anti-factor Xa Activity of Edoxaban in Patients With Moderate to Severe Renal Insufficiency
1. To provide reference for clinical rational use of edoxaban; 2. Optimize the individualized dosing regimen of edoxaban.
- Conditions
- Gene Polymorphism, Edoxaban, Renal Insufficiency
- Trial name
- NCT06431789
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Yi Han
Congenital Heart Disease, Unfractionated Heparin
Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)
This study aims to compare the accuracy of two different blood sampling methods from a central venous catheter (CVC) for measuring anti-Xa activity in children receiving unfractionated heparin (UFH) from this CVC.
- Conditions
- Congenital Heart Disease, Unfractionated Heparin, Anti Xa Activity
- Trial name
- COMPAXE-HNF (NCT07365670)
- Testing
- blood sampling for measuring anti-Xa activity, measurement of anti-XA activity
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients
The purpose of this study is to determine whether a circadian rhythm exists in anti-FXa levels and AT3 activity in hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis
- Trial name
- NCT07856641
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Nephrotic Syndrome
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
The primary objective is to test the hypothesis that enoxaparin efficacy is reduced in severe nephrotic syndrome. Another purpose is to compare two dosing regimens.
- Trial name
- ENOX-inNS (NCT04558892)
- Testing
- Enoxaparin
- Where
- Poland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Military Institute od Medicine National Research Institute
Cancer, Rivaroxaban
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.
- Conditions
- Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis
- Trial name
- VALERIA (NCT04999176)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- Brazil
- Volunteers
- 440 people
- Sponsor
- André Luiz Malavasi Longo de Oliveira
Differences in Laboratory Coagulation Parameters
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery.
- Trial name
- NCT00986635
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Bariatric Surgery, Anti-Xa Activity
The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.
Blood clots in the legs or lungs (called venous thromboembolism or VTE) are one of the most serious complications after weight loss surgery.
- Conditions
- Bariatric Surgery, Anti-Xa Activity, VTE (Venous Thromboembolism), Obesity & Overweight
- Trial name
- The OAT-RCT (NCT07559643)
- Testing
- Anti-Xa Activity Monitoring, Tinzaparin (Leo), enoxaparin
- Where
- Ireland
- Volunteers
- 180 people
- Sponsor
- University College Dublin
Acute Coronary Syndrome, Myocardial Infarction
Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
H-REPLACE trial is a prospective, randomized, open-label, active-controlled, multicenter study in participants with ACS (STEMI or NSTEMI, unstable angina).
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- H-REPLACE (NCT03363035)
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Enoxaparin
- Where
- 24 sites in China
- Volunteers
- 2,055 people
- Sponsor
- Second Xiangya Hospital of Central South University
Healthy
Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin
Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
- Trial name
- NCT00618579
- Testing
- LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ThromboGenics
Hypertriglyceridemia
Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma
Some hemostasis techniques require spectrophotometric measurements. These are then subject to interference from the sample's lipemia (postprandial, hypertriglyceridemia, etc.), which risks distorting the results; this is…
- Trial name
- LCGV (NCT07200674)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Strasbourg, France
Major Orthopaedic Surgery and Renal Impairment
Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.
Fondaparinux is an antithrombotic agent having already received a regulatory approval by the European Authorities in venous thromboembolic event prevention after major orthopaedic surgery, as total hip replacement (THR), total…
- Trial name
- PROPICE (NCT00555438)
- Testing
- fondaparinux 1.5 mg/day
- Where
- 29 sites in France
- Volunteers
- 451 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Acute Coronary Syndrome, Factor X
Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome
This study is a clinical trial monocentric, open, randomized ENOXA ® versus LOVENOX ®, conducted on two parallel groups of patients admitted in emergency for acute coronary syndrome.
- Trial name
- AXA (NCT01687491)
- Testing
- ENOXA®, LOVENOX®
- Where
- Tunisia
- Volunteers
- 179 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Morbid Obesity, Obesity
Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery
After bariatric surgery , thromboembolics complications are major cause of mortality. However, in obese patients, thromboprophylaxia is a controversy.
- Conditions
- Morbid Obesity, Obesity, Surgery
- Trial name
- NCT01064596
- Testing
- blood samples
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Acute Coronary Syndrome
Enoxamed Study in the Treatment of Acute Coronary Syndromes
Because of their anti-Xa and ease of administration activity, the Low molecular weight heparin represent an attractive alternative to the unfractionated heparin.
- Trial name
- ENOXAMED (NCT02152423)
- Testing
- LOVENOX, ENOXAMED
- Where
- Tunisia
- Volunteers
- 50 people
- Sponsor
- University of Monastir
Unfractionated Heparin Treatment
Evaluation of the Effect of Dextran Sulphate on Anti-Xa Activities Measured
The measurement of anti-Xa activity is classically used for the dose adjustement of unfractionated heparin (UFH) treatment and to monitor reversal of UFH by protamine during cardiac surgery with cardiopulmonary bypass (CPB).
- Trial name
- DEXHEP (NCT04700670)
- Testing
- measurement of anti-Xa activities
- Where
- 8 sites in France
- Volunteers
- 164 people
- Sponsor
- Rennes University Hospital
Endstage Renal Disease
LMWH Infusion as Anticoagulation for Home HD
There is a lack of data in the literature about the use of low-molecular weight heparin (LMWH) as anticoagulation for nocturnal home hemodialysis (NHHD).
- Trial name
- NCT02957877
- Testing
- Nadroparin, Unfractionated heparin
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- Alice Ho Miu Ling Nethersole Hospital